GPR14 polypeptides

US6133420A · kind A · utility

Assignees

• SmithKline Beecham Limited · US
• SmithKline Beeacham P.L.C. · GB

Inventors

• Robert S. Ames · Havertown, US
• Henry M. Sarau · Harleysville, US
• James J. Foley · Radnor, US
• Usman Shabon · Collegeville, US
• Derk J. Bergsma · Berwyn, US
• Jonathan K. Chambers · Hyde, GB

Key dates

• Filing date: Apr 10, 1998
• Grant date: Oct 17, 2000
• Expiry date: Apr 10, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K48/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human GPR14 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Human GPR14 polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.